Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01223001 · ClinicalTrials.gov registry record · Phase 2
Feasibility Study of Duloxetine in the Treatment of Depression in Patients With Traumatic Brain Injury
A Phase 2 study, sponsored by Rehabilitation Hospital of Indiana.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT01223001 is a Phase 2 study that was terminated before completion, run by Rehabilitation Hospital of Indiana. The registered enrollment target is 8 participants.
The verdict
NCT01223001, a Phase 2 study, was terminated before completion, sponsored by Rehabilitation Hospital of Indiana.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
The primary objective of the study is to compare the efficacy of duloxetine 60 mg by mouth daily with placebo in the prevention of depression associated with mild/moderate traumatic brain injury and to enhance cognitive function.
Interventions
- DRUG Duloxetine
- DRUG Sugar pill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 1996-09 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01223001
The ClinicalTrials.gov registry entry for NCT01223001 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rehabilitation Hospital of Indiana, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Duloxetine is the first listed.
NCT01223001 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01223001 about?
NCT01223001 is a clinical study titled "Feasibility Study of Duloxetine in the Treatment of Depression in Patients With Traumatic Brain Injury". The primary objective of the study is to compare the efficacy of duloxetine 60 mg by mouth daily with placebo in the prevention of depression associated with mild/moderate traumatic brain injury and to enhance cognitive function.
What is the current status of trial NCT01223001?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 1996-09. Estimated completion is 2011-07.
What interventions are being tested in trial NCT01223001?
The interventions under investigation include: Duloxetine (DRUG), Sugar pill (DRUG).
Who is sponsoring clinical trial NCT01223001?
This trial is sponsored by Rehabilitation Hospital of Indiana, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.